Found: 17
Select item for more details and to access through your institution.
AB1601 Phase 2 Study of ABvac40, an Anti‐Aβ40 Vaccine: Safety and Immunogenicity of a Cross‐Over Extension.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082952
- By:
- Publication type:
- Article
Contribution of clinical information to the predictive performance of plasma Aβ levels for Aβ PET positivity.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082471
- By:
- Publication type:
- Article
AB1601 topline results – Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer's Disease (Vm‐AD).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.065633
- By:
- Publication type:
- Article
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 2, p. 283, doi. 10.1002/alz.12395
- By:
- Publication type:
- Article
Aβ42/Aβ40 ratio in plasma predicts amyloid‐PET status in amnestic‐MCI patients.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.057231
- By:
- Publication type:
- Article
Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052117
- By:
- Publication type:
- Article
Safety, tolerability and immunogenicity of an active anti-Aβ<sub>40</sub> vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial.
- Published in:
- Alzheimer's Research & Therapy, 2018, v. 10, p. 1, doi. 10.1186/s13195-018-0340-8
- By:
- Publication type:
- Article
AN ACTIVE ANTI-AB40 VACCINE (ABVAC40) PROVED TO BE SAFE AND IMMUNOGENIC IN THE PHASE I CLINICAL TRIAL.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P199, doi. 10.1016/j.jalz.2016.06.348
- By:
- Publication type:
- Article
Beta-amyloid-17 is a major beta-amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Neprilysin Is Poorly Expressed in the Prefrontal Cortex of Aged Dogs with Cognitive Dysfunction Syndrome.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Neprilysin Is Poorly Expressed in the Prefrontal Cortex of Aged Dogs with Cognitive Dysfunction Syndrome.
- Published in:
- International Journal of Alzheimer's Disease, 2014, p. 1, doi. 10.1155/2014/483281
- By:
- Publication type:
- Article
Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity.
- Published in:
- Frontiers in Aging Neuroscience, 2023, v. 15, p. 1, doi. 10.3389/fnagi.2023.1126799
- By:
- Publication type:
- Article
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 11, p. 1375, doi. 10.1001/jamaneurol.2021.3180
- By:
- Publication type:
- Article
Clinical utility of an antibody‐free LC‐MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study.
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023, v. 15, n. 2, p. 1, doi. 10.1002/dad2.12451
- By:
- Publication type:
- Article
The global Alzheimer's Association round robin study on plasma amyloid β methods.
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021, v. 13, n. 1, p. 1, doi. 10.1002/dad2.12242
- By:
- Publication type:
- Article
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
- Published in:
- Alzheimer's Research & Therapy, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13195-022-01143-z
- By:
- Publication type:
- Article
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort.
- Published in:
- Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00911-7
- By:
- Publication type:
- Article